Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News Palatin Technologies completes Phase 2 obesity trial with MC4R bremelanotide and GLP-1/GIP tirzepatide Palatin Technologies, Inc. has announced the completion of its Phase 2 BMT-801 clinical trial, a study evaluating the… byPallavi MadhirajuFebruary 6, 2025